NZ-107 is an orally active leukotriene receptor antagonist. NZ-107 can inhibit anaphylaxis reaction. NZ-107 can be used for the researches of inflammation and immunology [1].
In Vivo, NZ-107 (50 mg/kg for i.p. or 100 mg/kg for p.o.) suppresses 48-h homologous passive cutaneous anaphylaxis reaction and Histamine -, Leukotriene C4 - and Leukotriene D4 -induced skin reactions in rats[1].
References:
[1]. Suda H, et al. Effects of a newly synthesized leukotriene antagonist, NZ-107, on immediate-type hypersensitivity reaction in rats and guinea-pigs. Prostaglandins Leukot Essent Fatty Acids. 1992 Sep;47(1):41-9.
In Vivo, NZ-107 (50 mg/kg for i.p. or 100 mg/kg for p.o.) suppresses 48-h homologous passive cutaneous anaphylaxis reaction and Histamine -, Leukotriene C4 - and Leukotriene D4 -induced skin reactions in rats[1].
References:
[1]. Suda H, et al. Effects of a newly synthesized leukotriene antagonist, NZ-107, on immediate-type hypersensitivity reaction in rats and guinea-pigs. Prostaglandins Leukot Essent Fatty Acids. 1992 Sep;47(1):41-9.